Levels of Inflammatory Markers in the Treatment of Stroke—An SPS3 Ancillary Study (LIMITS)
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Levels of Inflammatory Markers in the Treatment of Stroke|
- Ischemic stroke, myocardial infarction, death. [ Time Frame: 5 years ]
- Major Cognitive Decline. [ Time Frame: 5 years ]
Biospecimen Retention: Samples Without DNA
|Study Start Date:||June 2005|
|Estimated Study Completion Date:||January 2017|
|Primary Completion Date:||April 2012 (Final data collection date for primary outcome measure)|
SPS3 patient cohort
All SPS3 patients who participate in Baseline and 1-Year F/U blood draw
Inflammation is increasingly recognized as playing a central role in atherosclerosis and coronary artery disease. And, peripheral blood markers of inflammation have been associated with incident and recurrent cardiac events. The relationship of these risk markers—which have the potential to be modified—to prognosis after ischemic stroke is less clear.
The Levels of Inflammatory Markers in the Treatment of Stroke (LIMITS) study will address questions about the role of inflammatory markers in secondary stroke prevention in a cost-effective manner using the well-established framework of the Secondary Prevention of Small Subcortical Strokes (SPS3) trial. The SPS3 trial is an ongoing Phase 3, multicenter secondary stroke prevention trial that focuses on preventing stroke recurrence in people with small vessel ischemic stroke, or lacunes.
The overall purpose of the LIMITS study is to determine if serum levels of inflammatory markers—such as hsCRP, serum amyloid A (SAA), CD40 ligand (CD40L), and monocyte chemoattractant protein-1 (MCP-1)—predict recurrent stroke and other vascular events among people with a history of small artery ischemic stroke. The project will also determine if these markers predict which people will respond best to dual antiplatelet therapy with clopidogrel and aspirin.
The specific aims of LIMITS are to determine if hsCRP, SAA, CD40L, and MCP-1 levels are independent risk factors for recurrent ischemic stroke, and for recurrent ischemic stroke, myocardial infarction, and death in participants in the SPS3 trial after adjusting for demographic and traditional stroke risk factors, and other treatments, using a prospective cohort of people with small subcortical strokes from the SPS3 trial. LIMITS also aims to compare the efficacy of dual versus single antiplatelet therapy among participant groups with and without elevated baseline inflammatory marker levels for the outcome of a.) recurrent stroke, and b.) recurrent ischemic stroke, myocardial infarction, or death.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00579306
Show 45 Study Locations
|Principal Investigator:||Mitchell S. Elkind, MD, MS, FAAN||Columbia University|
|Principal Investigator:||Oscar Benavente, MD||UTHSC San Antonio (SPS3 Principal Investigator)|
|Principal Investigator:||Robert Hart, MD||UTHSC San Antonio (SPS3 Principal Investigator)|